BRAF and non-small cell lung carcinoma: Around 4% of NSCLC patients have a mutation in the B-Raf proto-oncogene (BRAF), but the V600E mutation is present in only half of such patients, who as a result are resistant to BRAF inhibitors (the V600E mutation is associated with a better response to BRAF-targeted therapy) (26).